The clinical benefit of HDC/LD-IL-2 in AML may inspire further development of immunotherapeutic strategies for remission maintenance in AML, including alternative strategies to target myeloid-cell-related immunosuppression and/or alternative means to achieve the optimal activation of anti-leukemic lymphocytes. The gene discussed is IL2; the disease is acute myeloid leukemia.